Tuesday, June 19, 2007

ESC - Summary reports and slides are available online during the Heart Failure 2007 Congress in Hamburg from 9 to 12 June 2007.

Scientific Reports

Heart Failure 2007 Congress

The following presentations were selected by the Scientific Committee of the Heart Failure Association of the ESC as of particular interest.

Please click on title to see session details.

Summary reports and slides are available online during the Heart Failure 2007 Congress in Hamburg from 9 to 12 June 2007.------------------------------------------------------------------------------------------------

Future of Biomarkers in Heart Failure Prof Eugène BraunwaldEugene Braunwald, M.D. is the Distinguished Hersey Professor of Medicine at Harvard Medical School, and Chairman of the TIMI Study Group at the Brigham and Women’s Hospital.Slides (PDF 1,7 Mb)
BNP is is an obligatory biomarker for longterm management of chronic heart failure - ProProf. Guillaume JondeauSummary: Despite advances in medical therapy of heart failure, mortality remains high. A new approach would be to improve monitoring of patients with chronic heart failure. Biomarkers such as BNP clearly rises this possibility and indications are coming from tials that use of this new parameter is associated with decreased hospitalisation rate.Report Slides

Levosimendan is a firstline drug in the management of acute heart failure - ProProf. Ferenc FollathSummary: The efficacy of levosimendan, a novel drug with positive inotropic and vasodilating actions, was well documented in patients with decomepensated chronic heart failure with high filling pressures and low cardiac output. Proper pretreatment evaluation is essential to select suitable patients for application as a firstline treatment and to avoid problems due to excessive vasodilation.Slides
Levosimendan is a firstline drug in the management of acute heart failure - ContraProf. John ClelandSummary: Levosimendan proved superior to dobutamine in terms of haemodynamics and survival when studied in patients with severe chronic heart failure in the LIDO study. However, two large studies of levosimendan in acute heart failure failed to show convincing evidence of benefit overall on morbidity or mortality. A modest improvement in symptoms was observed compared to placebo in one study which requires confirmation. Important benefits might have occurred in some subgroups of patients but this also requires confirmation.Slides

Detection and treatment of depression in routine care of patients with heart failureProf. Christiane E AngermannSummary: On systematic screeening, depression is frequently diagnosed amongst patients with chronic heart failure, and is known to carry an adverse prognosis. Up to now, no efficacy data regarding hard clinical endpoints are available for any treatment modality of depression in this patient population; however, selective serotonin re-uptake inhibition may favourably influence the mortality risk by improving health behaviour and/or via direct modulation of biological pathways.Report Slides

Haemodynamic monitoring: tool or toy? Assoc.Prof. Gerasimos FilippatosSummary: Hemodynamic variables have been considered necessary to guide treatment in critically ill heart failure patients but recent trials did not show any benefit from pulmonary artery catheter (PAC) use. However, the detrimental outcomes may not emanate from the use of a PAC per se but from the lack of effective therapies, lack of knowledge about appropriate use of information received from the PAC or because the information is obtained very late in the course of the disease. New devices could provide additional insight into the difficult problem of early evaluation and management of patients with heart failure.Slides
The adult human atrium a realistic cell source for therapy?Prof. Pieter DoevendansSummary: The human atrial auricle contains cardiomyocyte progenitor cells. These cells are present in small groups and can be grown as stem cells in a high volume and differentiated very efficiently into human cardiomyocytes. Potentially these cells can be used for cell transplantation and tissue engineering.

No comments: